Multidrug-resistant strains of Klebsiella pneumoniae are a problem in many hospitals. In 1999, the molecular epidemiology of K. pneumoniae with extended-spectrum b-lactamases (ESBLs) was studied at 15 hospitals in Brooklyn. Of 824 unique patient isolates, 34% were presumptive ESBL producers. Of this subset, 34% were susceptible to cefoxitin, 42% to ciprofloxacin, 48% to ceftriaxone, 55% to piperacillin-tazobactam, 57% to amikacin, and 86% to cefepime. Ribotype analysis revealed 87 unique types. However, 2 clusters accounted for 35% of isolates and were present in most of the hospitals. One cluster was significantly more resistant to most antibiotics. Although there was a predominance of SHV-5, considerable heterogeneity of b-lactamases was evident, even among isolates of the same cluster. A correlation was found between the use of cephalosporins and the prevalence of ESBL-producing strains of K. pneumoniae at each hospital. Our data suggest that there is an advanced outbreak of multidrug-resistant K. pneumonia infection that is affecting all Brooklyn hospitals.
units (ICUs) [2] . However, community-acquired infection with ESBL ϩ K. pneumoniae has been reported, primarily involving patients admitted to the hospital from nursing homes [3] . Because nursing-home patients are frequently admitted to 11 hospital and because transmission of resistant K. pneumoniae can occur within nursing homes, it is not surprising that these strains can be transferred from one hospital to another. Although institutional outbreaks of ESBL ϩ K. pneumoniae infection have been well described, less is known about the regional epidemiology and extent of interhospital spread of these organisms. A previous report documented an unusually high prevalence of ESBL ϩ K. pneumoniae at hospitals in Brooklyn, New York [4] . For the present article, we assessed the evolution of this problem in the city of Brooklyn by performing automated ribotyping of presumptive ESBL ϩ isolates and b-lactamase characterization of selected isolates. Finally, the relationship between hospital antibiotic usage patterns and resistance rates was evaluated. [5] . Ceftazidime was tested alone and in combination with clavulanic acid. The concentrations of clavulanic acid and tazobactam were fixed at 4 mg/mL. NCCLS break points for susceptibility were used [5] . For study purposes, isolates with a ceftazidime or cefpodoxime MIC of у2 mg/mL were considered presumptively ESBL ϩ .
MATERIALS AND METHODS

Bacterial strains.
Genetic analysis. Genetic fingerprinting was performed using the Riboprinter Microbial Characterization System (Qualicon). It has been shown elsewhere [6] that results obtained by this method correlate well with the results of PFGE analysis of K. pneumoniae. Automated ribotyping was done for nearly all ESBL ϩ isolates. Ribosomal DNA was digested with
EcoRI, according to the manufacturer's instructions. b-Lactamase characterization.
Isoelectric focusing was performed on selected ESBL ϩ isolates. Crude cell extracts were focused on an ampholine gel (pH range, 3-10; Pharmacia) along with standard strains that have known b-lactamases. b-Lactamases were identified with nitrocefin (50 mg/mL), according to techniques described elsewhere [7] . b-Lactamases were amplified by PCR with use of specific nucleotide primers for bla TEM , bla SHV , and bla ACT-1 , with use of methods described elsewhere [8, 9] . PCR products were cloned into pCR 2. 
RESULTS
Susceptibility studies.
A total of 824 unique patient isolates of K. pneumoniae were collected during the 3-month period. Of the 824 isolates, 48% were recovered from urine cultures, 19% from respiratory tract cultures, 13% from skin and softtissue cultures, 11% from blood cultures, and 9% from miscellaneous or unknown types of cultures. On the basis of nosocomial infection data gathered at 7 of 15 hospitals, ∼23% of the isolates caused nosocomial infections [10] . The results of the susceptibility testing are shown in table 1. Overall, 34% of isolates were presumed to produce ESBLs. ESBL ϩ K. pneumoniae were detected at all 15 hospitals, at rates ranging from 10% to 55% of K. pneumoniae isolates. Among the subgroup of ESBL ϩ K. pneumoniae isolates, approximately one-half remained susceptible to amikacin, ciprofloxacin, or piperacillin-tazobactam and only 28% remained susceptible to trimethoprim-sulfamethoxazole (table 1) . Moreover, only one-third of ESBL ϩ isolates were susceptible to cefoxitin, and only two-thirds were susceptible to cefotetan or the combination of ceftazidime plus clavulanic acid. The addition of clavulanic acid to ceftazidime produced a у8-fold decrease in the ceftazidime MIC for only 60% of ESBL ϩ isolates. Although the majority of ESBL ϩ isolates remained susceptible to cefepime, the activity of this agent was markedly reduced; MICs were typically in the 1-8 mg/mL range. Only the carbapenems retained activity against nearly all isolates; the activity of meropenem was generally 4-8-fold greater than that of imipenem. Three isolates, from 2 hospitals, were not susceptible to imipenem (MIC range, 8 to у64 mg/mL).
Comparison of data from hospitals in western Brooklyn with that from hospitals in eastern Brooklyn revealed that the overall rates of ESBL ϩ K. pneumoniae were similar (37% vs. 33% of K. pneumoniae isolates, respectively; P not significant). However, ESBL ϩ isolates from western Brooklyn hospitals were more likely to be resistant to cefotetan (50% vs. 26% of isolates resistant; ) and cefepime (33% vs. 16% of isolates re-P ! .001 sistant;
). Additionally, fewer isolates from western hos-P ! .01 pitals had a у8-fold decrease in ceftazidime MIC when ceftazidime was combined with clavulanic acid (50% vs. 66% of isolates showing a reduction; ). In addition, cluster 2 iso-P ! .001 lates were more likely to have reduced carbapenem susceptibility (imipenem MIC of у2 mg/mL) than were other ESBL ϩ isolates (32% vs. 6%;
). Finally, cluster 2 isolates ac-P ! .001 counted for a greater proportion of ESBL ϩ isolates in western hospitals than in eastern ones (21% vs. 11%; ).
Isoelectric focusing revealed multiple b-lactamases in the great majority of isolates tested (table 3). Of 22 cluster 1 isolates analyzed, 19 had blactamases with an isoelectric point (pI) of 8.2; the corresponding b-lactamase was identified as SHV-5 in some of the strains. Of 14 cluster 2 isolates analyzed, 5 possessed a b-lactamase with a pI of 19.0. The hydrolysis of nitrocefin by these enzymes was inhibited by oxacillin, which suggests that these were class C b-lactamases. ACT-1, a class C b-lactamase known to be present on plasmids in K. pneumoniae in New York City [9] , was indeed identified in some strains. The presence of this cephalosporinase may partly account for the greater resistance rates (particularly against cephamycins and b-lactamase-inhibitor combinations) of isolates in cluster 2. However, many isolates without this bLactamase were also resistant to b-lactamase inhibitors (table  3) . SHV-5 was the predominant ESBL identified, although several other SHV-type ESBLs were also identified (SHV-2, SHV-7, SHV-27, and SHV-28). In addition, several non-ESBL blactamases were identified, including TEM-1, SHV-1, and SHV-11.
Antibiotic usage. The antibiotic usage at 12 of 15 hospitals is summarized in table 4. In a multivariate analysis that included each class of antibiotics, the average daily census, and the average length of stay for these hospitals, only the use of cephalosporins plus aztreonam was directly correlated with the prevalence of ESBL ϩ strains of K. pneumoniae at each hospital ( ) . P p .014 [3, [13] [14] [15] [16] [17] . Indeed, the 2 largest clusters of ESBL ϩ isolates in the present study were detected in most of the hospitals, and one of these clusters was overrepresented at hospitals in the western neighborhoods of the borough. However, a total of 87 unique ribotypes of ESBL ϩ K.
pneumoniae were detected, a finding that is in sharp contrast to other reports of the spread of a single epidemic strain in a region [14, 16] . Also, heterogeneous b-lactamases were identified even within a given cluster, which is a testimony to the complexity of the outbreak we describe. Taken together, these findings document a high level of intrahospital and interhospital transmission of particular strains, as well as dissemination of a multitude of b-lactamases among strains in the region. These data suggest that the evolution of the outbreak of ESBL ϩ K. pneumoniae in the city of Brooklyn is far advanced. The susceptibility findings of our study present several additional concerns. Many ESBL ϩ K. pneumoniae retain susceptibility to cephamycins and to the effects of clavulanic acid and tazobactam. In this survey, nearly one-half of isolates were resistant to the b-lactamase inhibitors, and two-thirds were resistant to cefoxitin. This resistance pattern could be due to presence of class C enzymes [9, [18] [19] , which were found in some of our isolates (particularly in one cluster). However, many inhibitor-resistant isolates did not carry this enzyme, which suggests that other mechanisms are involved. These mechanisms may include hyperproduction of ESBLs [20] , altered outer membrane porins [21, 22] , and/or inhibitor-resistant TEM enzymes [23, 24] . Also, SHV enzymes (the predominant ESBLs in our area) tend to be more refractory to the activity of b-lactamase inhibitors when the inoculum is increased [25] . The NCCLS has recommended confirmation of the presence Table 3 . Characterization of b-lactamases in isolates of Klebsiella pneumoniae. of ESBLs by performance of phenotypic tests that demonstrate a response to b-lactamase inhibitors [5] . In our region, the frequency of resistance to b-lactamase inhibitors, despite the confirmed presence of ESBLs, undermines the usefulness of the NCCLS guidelines. Clearly, in established epidemics, such as the one we describe, performing the additional confirmatory test adds little useful information to the result of the screening test.
Patient-to-patient transmission of ESBL ϩ K. pneumoniae has been documented in several studies and has been correlated with the rectal colonization of patients [14, 23, 26] , contamination of environmental surfaces and the hands of clinical staff [14, 27] , and the transfer of patients between hospitals and nursing homes [3, 13, 15] . Infection-control measures tend to be most successful in the control of outbreaks of infection with a single strain that has affected a confined area of a hospital. In one hospital, intense infection-control strategies directed against ESBL ϩ bacteria reduced their prevalence [28] ; this occurred while the use of cephalosporins was increased. Similar aggressive infection-control strategies may need to be applied in all acute-and chronic-care facilities in our region in order to have an impact in reducing the spread of ESBL ϩ K. pneumoniae. The present study also found a significant correlation between cephalosporin use and ESBL ϩ K. pneumoniae, which is consistent with the findings of other reports [29] [30] [31] . It should be acknowledged, however, that the antibiotic usage data in the present study were heterogeneous, and our results should be interpreted with caution. Decreasing the use of cephalosporins has successfully controlled several single-hospital outbreaks of infection with ESBL ϩ organisms [29] [30] [31] . Whether enacting similar policies throughout a region would prove effective remains to be determined. In summary, ESBL ϩ K. pneumoniae have become firmly entrenched in Brooklyn hospitals. Given our current epidemiological data regarding K. pneumoniae and given the fact that ESBL production is also relatively common among Escherichia coli and Proteus mirabilis [4] , controlling the spread of ESBL ϩ K. pneumoniae in our city will be difficult. In the face of increasing fiscal constraints at many health care facilities, support for additional resources for aggressive infection-control measures and restrictive antibiotic usage policies may not be given priority. Given the degree to which they have spread, these organisms should be viewed as a citywide public health issue rather than an individual hospital problem.
